An oral drug to treat chronic hepatitis B in adults has won FDA approval. Entecavir (Baraclude) works by preventing the hepatitis B virus from replicating. In clinical trials, it significantly decreased liver inflammation and the degree of liver fibrosis. Adverse reactions included headache, fatigue, dizziness, abdominal pain, and diarrhea. Patients taking Baraclude should undergo regular liver function monitoring.
Taken once a day, Baraclude is available as a tablet and an oral solution.